By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
No open-market selling at Sutro Biopharma, Inc. in the past year, which is unusual. Instead five executives and directors picked up about $90,000 worth of STRO.
The largest purchase came from MATSUI CONNIE (Director), about $40,000. That includes C-suite money, which tends to get the most attention.
97 investment managers listed STRO in their latest 13F filings (Q2 2026); more funds bought than sold. Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
Are insiders buying or selling STRO stock?
In the last 12 months Sutro Biopharma, Inc. insiders made open-market purchases worth about $90,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in STRO?
The most recent open-market insider trade in STRO was filed on 2025-10-16.
How many institutions own STRO?
97 investment managers reported holding STRO in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded STRO?
No congressional trades in STRO were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).